Discovery of Zika Virus NS2B/NS3 Inhibitors That Prevent Mice from Life-Threatening Infection and Brain Damage
Antonio Coluccia, Michela Puxeddu, Marianna Nalli, Chih‐Ku Wei, Yu‐Hsuan Wu, Eloise Mastrangelo, Tasneem Elamin, Delia Tarantino, Joachim J. Bugert, Benno Schreiner, Juliane Nolte, Frank Schwarze, Giuseppe La Regina, Jin‐Ching Lee, Romano Silvestri
Abstract
High Resolution Image Download MS PowerPoint Slide Zika virus (ZIKV) infection, which initially was endemic only in Africa and Asia, is rapidly spreading throughout Europe, Oceania, and the Americas. Although there have been enormous efforts, there is still no approved drug to treat ZIKV infection. Herein, we report the synthesis and biological evaluation of agents with noncompetitive mechanism of the ZIKV NS2B/NS3 protease inhibition through the binding to an allosteric site. Compounds 1 and 2 showed potent activity in both enzymatic and cellular assays. Derivative 1 efficiently reduced the ZIKV protein synthesis and the RNA replication and prevented the mice from life-threatening infection and the brain damage caused by ZIKV infection in a ZIKV mouse model.